Sumitomo Chemicals Q3 Review - Healthy Beat; Long-Term Growth Intact: Nirmal Bang

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Nirmal Bang Report.Sumitomo Chemicals India Ltd.'s Q3 FY22 profit after tax was a 43.2% beat versus our estimate due to the 14.2% beat on revenue and 310 basis points beat on Ebitda margin despite 43 bps miss on gross margin. Positives: healthy long-term prospects, supported by revenue/earnings per share compound annual growth rate of 16.8%/27.3% over FY22E-24E,return on invested capital of 48.3%/46.3% in FY23E/FY24E andhealthy growth in net cash to Rs 13.73 billion by FY24E. Key catalysts: Sumitomo Chemicals offers multi national company proxy exposure in the Indian crop protection chemical sector based on the potential forgrowth in premium/generic products across categories in domestic/export markets andnew orders from Sumitomo Chemical (Japan) for the five molecules contracted to commence from FY24E..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Sumitomo Chemicals Q3 Review - Healthy Beat; Long-Term Growth Intact: Nirmal Bang

Sumitomo Chemicals Q3 Review - Healthy Beat; Long-Term Growth Intact: Nirmal Bang

Choose a plan